製品番号: HY-N0202

Atractylenolide II

(別名: Asterolide; アトラクチレノリドII)

3 Cited Publications

カスタマーレビュー

Based on 3 publication(s) in Google Scholar

Atractylenolide II (Asterolide) is a sesquiterpenoid compound. Atractylenolide II can induce G1 phase cell cycle arrest and apoptosis in B16 melanoma cells. Atractylenolide II is an orally effective anticancer agent that can exert anti-melanoma effects by inhibiting the STAT3 signaling pathway. In addition, Atractylenolide II has been shown to ameliorate myocardial fibrosis, oxidative stress, and neuroprotective activity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.89%
CAS 番号: 73069-14-4
分子式: C₁₅H₂₀O₂
分子量:232.32

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Atractylenolide II 構造式

CAS 番号: 73069-14-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
Publications (3)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

p-STAT3

ERK アイソフォーム固有の製品をすべて表示 :

p38 MAPK アイソフォーム固有の製品をすべて表示 :

Akt アイソフォーム固有の製品をすべて表示 :

Src アイソフォーム固有の製品をすべて表示 :

STAT アイソフォーム固有の製品をすべて表示 :

体外実験

Atractylenolide II (50-100 μM; 48 h) can inhibit the proliferation of B16 cells (IC₅₀: 82.3 μM), increase apoptosis and cause G1 phase cell cycle arrest, affect the expression or activity of cell cycle and apoptosation-related proteins, mainly involved in p38 activation and the inactivation of ERK and Akt^[1].
Atractylenolide II (0.1-10 μM; 48 h) has protective effect on SH-SY5Y cells treated with MPP⁺^[2]. Atractylenolide II (20-40 μM; 48 h) shows anti-melanoma effect in B16 and A375 melanoma cells by inhibiting STAT3 signaling pathway^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

B16 cells
Concentration:

50, 75 and 100 μM
Incubation Time:

48 h
Result:

Increased the phosphorylation level of p38.
Inhibited the phosphorylation levels of ERK and Akt.

Western Blot Analysis^[3]

Cell Line:

B16 and A375 cells
Concentration:

20 and 40 μM
Incubation Time:

48 h
Result:

Reduced protein expression levels of phospho-STAT3, phospho-Src, as well as STAT3-regulated Mcl-1 and Bcl-xL in a dose-dependent manner.

体内実験

Atractylenolide II (12.5-25 mg/kg; Oral gavage; 14 days) has antitumor effect in a B16 xenograft mouse model^[3].
Atractylenolide II (10-60 mg/kg/d; Intraperitoneal injection; 8 weeks) improves myocardial fibrosis and oxidative stress in spontaneously hypertensive rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57/BL6 mice with a B16 xenograft model^[3]
Dosage:

12.5 and 25 mg/kg
Administration:

Oral gavage (i.g.); 14 days
Result:

Significantly inhibited tumor growth.
Inhibited the activation/phosphorylation of STAT3 and Src.

Animal Model:

Spontaneous hypertension rats^[4]
Dosage:

10, 30 and 60 mg/kg/d
Administration:

Intraperitoneal injection (i.p.); 8 weeks
Result:

Improved the body weight of spontaneous hypertension rats and enhanced myocardial function in a dose-dependent manner.
Effectively reduced cardiomyocyte apoptosis.
Inhibited the Collagen I, α-SMA, Fibronectin and Vimentin mRNA and protein expression levels.
Ameliorated oxidative stress by improving the activities of SOD and GSH-PX and lowering the contents of H₂O₂ and MDA, which reached about 80%.

化学情報

CAS 番号 73069-14-4
性状 Solid
分子量 232.32
分子式 C₁₅H₂₀O₂
Color White to off-white
SMILES

O=C1C(C)=C(C[C@@]23[H])[C@@](C[C@@]3(C)CCCC2=C)([H])O1
別名

Asterolide; アトラクチレノリドII
Structure Classification
- Terpenoids
- Sesquiterpenes
Initial Source
- Plants
- Compositae
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All Cell Proliferation/Viability AssayWBIFFlow CytometryELISA

Sort by:

Journal Impact Factor

Pharmacol Res

Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]

2020 May:155:104751. PMID: 32151678
Naunyn Schmiedebergs Arch Pharmacol

Atractylenolide II regulates the proliferation, ferroptosis, and immune escape of hepatocellular carcinoma cells by inactivating the TRAF6/NF-κB pathway. [Abstract]

2024 Oct;397(10):7697-7710. PMID: 38709266

Atractylenolide II purchased from MedChemExpress. Usage Cited in: Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct;397(10):7697-7710. [Abstract]

The cell viability of THLE-3 cells treated with 0, 12.5, 25, 50, 100, 200, and 400 μM Atractylenolide II (AT-II) for 48 h was examined by CCK-8 assays.

Atractylenolide II purchased from MedChemExpress. Usage Cited in: Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct;397(10):7697-7710. [Abstract]

The relative protein expression of xCT and GPX4 was examined by western blot after Hep3B and Huh7 cells were treated with 50, 100, and 200 μM Atractylenolide II (AT-II) for 48 h.

Atractylenolide II purchased from MedChemExpress. Usage Cited in: Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct;397(10):7697-7710. [Abstract]

The relative lipid ROS level was examined after Hep3B and Huh7 cells were incubated with 50, 100, and 200 μM Atractylenolide II (AT-II) for 48 h.

Atractylenolide II purchased from MedChemExpress. Usage Cited in: Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct;397(10):7697-7710. [Abstract]

The percent of CD8⁺ T cells was detected by fow cytometry incubated with 50, 100, and 200 μM Atractylenolide II (AT-II) for 48 h.

Atractylenolide II purchased from MedChemExpress. Usage Cited in: Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct;397(10):7697-7710. [Abstract]

The concentrations of IFN-γ were measured by ELISA incubated with 50, 100, and 200 μM Atractylenolide II (AT-II) for 48 h.
CUNY Hunter College

2020 Sep.

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (430.44 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.3044 mL

21.5220 mL

43.0441 mL

5 mM

0.8609 mL

4.3044 mL

8.6088 mL

10 mM

0.4304 mL

2.1522 mL

4.3044 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (281 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Ye Y, et al. Atractylenolide II induces G1 cell-cycle arrest and apoptosis in B16 melanoma cells. J Ethnopharmacol. 2011 Jun 14;136(1):279-82. [Content Brief]

[2]. Zhang N, et al. Two new compounds from Atractylodes macrocephala with neuroprotective activity. J Asian Nat Prod Res. 2017 Jan;19(1):35-41. [Content Brief]

[3]. Fu XQ, et al. Inhibition of STAT3 signalling contributes to the antimelanoma action of atractylenolide II. Exp Dermatol. 2014 Nov;23(11):855-7. [Content Brief]

[4]. Song X, et al. Atractylenolide II ameliorates myocardial fibrosis and oxidative stress in spontaneous hypertension rats. Technol Health Care. 2024;32(1):131-142. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.3044 mL	21.5220 mL	43.0441 mL	107.6102 mL
	5 mM	0.8609 mL	4.3044 mL	8.6088 mL	21.5220 mL
	10 mM	0.4304 mL	2.1522 mL	4.3044 mL	10.7610 mL
	15 mM	0.2870 mL	1.4348 mL	2.8696 mL	7.1740 mL
	20 mM	0.2152 mL	1.0761 mL	2.1522 mL	5.3805 mL
	25 mM	0.1722 mL	0.8609 mL	1.7218 mL	4.3044 mL
	30 mM	0.1435 mL	0.7174 mL	1.4348 mL	3.5870 mL
	40 mM	0.1076 mL	0.5381 mL	1.0761 mL	2.6903 mL
	50 mM	0.0861 mL	0.4304 mL	0.8609 mL	2.1522 mL
	60 mM	0.0717 mL	0.3587 mL	0.7174 mL	1.7935 mL
	80 mM	0.0538 mL	0.2690 mL	0.5381 mL	1.3451 mL
	100 mM	0.0430 mL	0.2152 mL	0.4304 mL	1.0761 mL

Keywords

Atractylenolide II

3 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Atractylenolide II

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

MAPK Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

MedChemExpress（MCE）の使用を引用している文献 Atractylenolide II